Preclinical Research, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.
Planta Med. 2011 Jul;77(11):1123-8. doi: 10.1055/s-0030-1270849. Epub 2011 Mar 7.
Extracts from different parts of hawthorn plants (Crataegus spp.) are used worldwide for the treatment of cardiovascular diseases. So far, almost all clinical studies have been conducted with standardized hydroalcoholic extracts from leaves and flowers. These trials with more than 4000 patients have provided evidence for clinical benefits in the therapy of mild chronic heart failure. Besides cardiotonic effects, recent pharmacological investigations indicate that hawthorn extracts also possess cardio- and vasoprotective properties. Thus, these extracts may also be employed in the prophylactic and therapeutic treatment of such conditions as endothelial dysfunction, atherosclerosis, coronary heart disease, or prevention of restenosis/reocclusion following peripheral endovascular treatment. In this review the pharmacological and clinical data relating to these standardized extracts are summarized.
山楂属植物（Crataegus spp.）的不同部位提取物在全球范围内被用于治疗心血管疾病。到目前为止，几乎所有的临床研究都是使用标准化的叶和花的水醇提取物进行的。这些涉及超过 4000 名患者的试验为轻度慢性心力衰竭治疗中的临床获益提供了证据。除了强心作用外，最近的药理学研究还表明，山楂提取物还具有心脏和血管保护作用。因此，这些提取物也可用于内皮功能障碍、动脉粥样硬化、冠心病等疾病的预防和治疗，或预防外周血管内治疗后的再狭窄/再闭塞。在这篇综述中，总结了与这些标准化提取物相关的药理学和临床数据。
